Drug Discovery · Cambridge, MA · Founded 2015 · Privately Held (backing)
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. Parabilis Medicines is based in Cambridge, MA and was founded in 2015. It is valued at about $920 million as of Oct 2026, set by institutional fund marks. It has raised $812 million across 3 recorded rounds; the latest was a $305 million Series F in Jan 2026.
PMV mark · valuation
$920.0M
Oct 2026
Priced at
its later-stage round
Jan 2026
Total raised
$812.0M
Last round
Later Stage VC (Series F)
Jan 2026
Cap table — not yet on record
Parabilis Medicines's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Where does Parabilis Medicines's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Parabilis Medicines's 3 recorded funding rounds.
